ArriVent BioPharma AVBP Income Statement (2023-2026)

NASDAQ AVBP
$29.54 +0.24 (+0.82%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

ArriVent BioPharma Quarterly Income Statement

Periods 14 quarters
Latest Jun 2026

ArriVent BioPharma reported net income of -$49.89M for the quarter ended Jun 2026. This income statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.) 1.29M2.00M2.67M2.14M25.05M33.51M33.69M33.71M34.04M37.49M40.85M42.45M45.31M48.32M
Operating items
Research & DevelopmentR&D 10.24M20.36M14.28M20.01M16.98M21.78M20.09M20.16M61.29M27.72M32.17M32.17M37.62M42.34M
Selling, General & AdministrativeSG&A 1.94M2.23M2.44M3.11M3.70M3.92M4.14M3.54M5.48M5.90M6.15M6.65M8.49M10.35M
Other Operating ExpensesOther Opex 1.68M1.94M2.08M1.46M2.15M2.44M1.92M2.26M2.31M3.76M
Operating ExpensesOpex 12.17M22.58M16.72M23.12M20.67M25.70M24.23M23.70M66.77M33.62M38.32M38.82M46.11M52.69M
Operating IncomeOp. Inc -12.17M-22.58M-16.72M-23.12M-20.67M-25.70M-24.23M-23.70M-66.77M-33.62M-38.32M-38.82M-46.11M-52.69M
EBIT -12.17M-22.58M-16.72M-23.12M-20.67M-25.70M-24.23M-23.70M-66.77M-33.62M-38.32M-38.82M-46.11M-52.69M
Non-operating items
Interest & Investment IncomeInt & Inv Inc 1.02M2.31M1.93M3.26M3.82M3.67M3.07M2.38M2.22M3.34M3.28M2.79M2.80M
Net income details
EBT -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M-49.89M
Profit After TaxPAT -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M-49.89M
Income from Continuing OperationsIncome (Continuing) -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M-49.89M
Consolidated Net IncomeConsol Net Inc. -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M-49.89M
Income towards Parent CompanyParent Net Inc -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M-49.89M
Net Income towards Common StockholdersNet Income -12.17M-21.57M-14.40M-21.19M-17.42M-21.87M-20.56M-20.63M-64.39M-31.40M-34.98M-35.54M-43.32M-49.89M
Additional items
EPS (Basic) -9.45-10.79-5.52-9.90-0.70-0.65-0.61-0.66-1.90-0.90-0.83-0.92-0.96-1.05
EPS (Diluted) -9.45-10.79-5.52-9.90-0.70-0.65-0.61-0.66-1.90-0.90-0.83-0.92-0.96-1.05
Shares Outstanding 1.29M2.00M2.61M2.14M25.05M33.50M33.58M31.47M33.90M35.01M41.91M38.46M45.07M47.61M
Shares Outstanding (Diluted)Shares Outstanding (Dil.) 1.29M2.00M2.61M2.14M25.05M33.50M33.58M31.47M33.90M35.01M41.91M38.46M45.07M47.61M
EBITDA -46.67M-53.21M

ArriVent BioPharma Income Statement API

Pull ArriVent BioPharma's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=AVBP&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY